Medtronic (NYSE: MDT) announced today that it launched its Avalus Ultra bioprosthesis heart valve in India.
The company designed the next-generation surgical aortic heart valve specifically to offer ease of use at implant. It provides a durable circular foundation and reliable performance for future transcatheter aortic valve in surgical aortic valves (TAV-in-SAV) reinterventions to support lifetime management for patients.
Other features of Avalus Ultra include a low profile and a polyetheretherketone (PEEK) base frame for consistent circularity. Medtronic said it has an industry-leading effective orifice area (EOA) that may allow for greater blood flow. It also features a radiopaque coil for clear visibility for future valve-in-valve procedures. The system offers a flexible sewing cuff for secure seating with minimal paravalvular leak (PVL) rates and replica sizers with simulated cuffs for precise sizing.
Avalus Ultra builds on 10 years of clinical experience and long-term durability from the original Avalus valve launched in 2017. The latest-generation valve picked up its own FDA clearance to treat aortic stenosis in January of this year. It offers an option for the surgical aortic valve replacement (SAVR) method of treating aortic valve disease.
Medtronic launched Avalus Ultra in the U.S. in April 2024, then launched it in Europe in October 2024.
“The Avalus Ultra valve is designed to simplify implantation, enhance reliability, and provide clinicians with a solution that supports consistent, long-term outcomes for their patients,” said Prateek Tiwari, senior director, Neuroscience and Specialty Therapies at Medtronic India. “Every feature reflects Medtronic’s commitment to advancing cardiac care, equipping surgeons with precise and dependable tools, and helping them deliver care that is tailored to each patient’s needs. Our aim is to support clinicians at every step of the surgical journey to deliver on our Medtronic mission to alleviate pain, restore health, and extend life.”
